Company: ACBM
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001640334-25-001999
Chunk: 21

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 2
Chunk 21
---
229 or $(0.00) per share (basic and diluted).

For the nine months ended September 30, 2025, we had no revenue or cost of revenue.  Our operating expenses were $137,647, which are primarily related to expenses and professional fees relating to our status as a public company. We also incurred interest expense to a minority stockholder of $6,025. As a result, we had a net loss of $143,672 or $(0.00) per share (basic and diluted).

For the nine months ended September 30, 2024, we had no revenue or cost of revenue.  Our operating expenses were $28,490, which are primarily relating to expenses and professional fees relating to our status as a public company. We also incurred interest expense to a minority stockholder of $3,134. As a result, we had a net loss of $31,624 or $(0.00) per share (basic and diluted).

Liquidity and Capital Resources

The following table summarizes our changes in working capital from December 31, 2024 to September 30, 2025:

  September 30,2025  December 31,2024  Change  % Change Current assets $4,323  $5,076  $(753)  (14.8)%Current liabilities $436,942  $326,946  $109,996   33.6%Working capital (deficiency)  $(432,619 ) $(321,870 ) $(110,749)  34.4%

The following table summarizes our cash flows for the nine months ended September 30, 2025 and 2024: 

  Nine Months EndedSeptember 30,   2025  2024 Cash used in operating activities $(170,925 ) $(26,177 )Cash provided by financing activities $174,772  $26,502 Cash at end of period $4,323  $701 

Cash used in operating activities of $170,925 for the nine months ended September 30, 2025 reflected primarily our net loss of $143,672 reduced by a decrease in accounts payable and accrued expenses of $35,563 and increased by imputed interest – related parties of $6,025 and security deposit of $2,285.

Cash used in operating activities of $26,177